Articles related to ADJUVANT TREATMENT
Phase 2 trial in oeso-gastric adenocarcinoma (OSA) showed pathologic complete response in 59% of patients. Data update expected at ASCO 2022.
Neo-adjuvant therapy with nivolumab and ipilimumab is associated with a high pCR rate in ptsd with MSI/dMMR resectable OGA.
Oncology, Medical May 10th 2022
Association of Circulating Tumor DNA Dynamics w. Clinical Outcomes in the Adjuvant Setting for Patients w. CRC from an Observational GALAXY Study in CIRCULATE – Japan
Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) might be used to identify patients who would benefit more from standard-of-care adjuvant chemotherapy by accurately assessing recurrence-risk post-surgery and by evaluating adjuvant chemotherapy efficacy. This analysis from the GALAXY study, an observational study monitoring MRD, evaluates the association of ctDNA dynamics with a short-term clinical outcome and ACT efficacy.
Oncology, Medical May 4th 2022
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
A literature review involving 24 recent studies yielded an update to ASCO’s recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.
Oncology, Medical May 4th 2022
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update
“For patients with T1cN1-2 or T2-4N0 (stage II or III), early-stage TNBC, the Panel recommends use of pembrolizumab (200 mg once every 3 weeks or 400 mg once every 6 weeks) in combination with neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery.”
Oncology, Medical April 26th 2022
Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy vs. Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)
Short-term radiotherapy with preoperative chemotherapy followed by surgery (total neoadjuvant therapy, TNT) was compared to standard long-term chemoradiotherapy in patients with locally advanced rectal cancer. At a median follow-up of 35.0 months, 3-year DFS was 64.5% and 62.3% in the TNT and CRT groups, respectively. There was no significant difference in metastasis-free survival or locoregional recurrence, but the TNT group had better 3-year overall survival than the CRT group (86.5% v 75.1%; P = .033). Treatment effects on DFS and overall survival were similar regardless of prognostic factors. The prevalence of acute grade III-V toxicities during preoperative treatment was 26.5% in the TNT group versus 12.6% in the CRT group (P < .001).
Oncology, Medical March 29th 2022
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients with Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
This retrospective cohort study included 2,833 patients with stage IB to IIIA NSCLC who enrolled in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study from August 18, 2014, to April 1, 2019. Although 93% received surgical resection, just 53% had adequate lymph node dissection and 57% received any adjuvant chemotherapy. The authors suggest more effort at optimizing use of proven therapies in this patient population.
Oncology, Medical March 22nd 2022